February 2015 – Policy & Medicine

New Poll Shows Majority of Americans Are Concerned About Pace of Medical Progress

FDA Postpones Advisory Committee Review of Celltrion’s Remicade Biosimilar

Drug Price Policy: New Transparency Bill Would Require Drug Companies To Report Costs For High Cost Drugs; Will Annuities Be The Future Payment Model For Expensive Medicine?

Physician Payments Sunshine Act: Vermont Gift Ban and Disclosure Law Update

Medtronic Subsidiary ev3 Pays $1.25 Million to Settle Allegations Related To Promotion

Market Research and the Physician Payments Sunshine Act: Has Physician Participation Declined Due To Open Payments?

Orphan Drugs Had A Big 2014, Including Unprecedented Approval Rates

FDA Accepts Apotex’s Neupogen Biosimilar Application: Raises Issues of How the Agency Will Address Exclusivity, Previous Warning Letters to Apotex

AstraZeneca Pays $7.9 Million To Resolve Kickback Allegations Related to PBM Formulary Placement

DOJ Enforcement Panel Focuses on Medical Device Companies